NCT06397469

Brief Summary

The goals of the proposed research are to first determine the minimal and/or optimal dose of a digital intervention required for cognitive enhancement, and then to examine the impact of several potential moderators of treatment effects (i.e., cognitive decline, AD polygenic hazard score, cardiovascular risk, and race/ethnicity). This knowledge gained from his high-impact study with transform the field of cognitive interventions, paving the way for a precision medicine model for cognitive enhancing interventions that improve quality of life for older adults and individuals with cognitive deficits at risk of developing dementia.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,000

participants targeted

Target at P75+ for not_applicable

Timeline
37mo left

Started Apr 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress41%
Apr 2024Jun 2029

Study Start

First participant enrolled

April 1, 2024

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

April 23, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 3, 2024

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2029

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2029

Last Updated

February 24, 2026

Status Verified

February 1, 2026

Enrollment Period

4.8 years

First QC Date

April 23, 2024

Last Update Submit

February 20, 2026

Conditions

Keywords

healthy agingattentioncognitiondementiainterventiondigitalbehavioralpreventiondeclinestress reductionQuality of life

Outcome Measures

Primary Outcomes (1)

  • Change on the Mobile Continuous Performance Task (CPT) over time

    The CPT is a 23-minute task, where participants are instructed to respond to target stimuli (squares at the top of the screen) and withhold responses to non-target stimuli (squares at the bottom of the screen). Performance will be quantified as: (1) mean reaction times, (2) standard deviation of reaction times (RTV), and (3) d-prime (comparing correct target detections or 'hits' to incorrect non-target detections or 'false alarms').

    baseline, immediate follow-up, and at a 6 month follow-up

Secondary Outcomes (1)

  • Change on the Adaptive Cognitive Evaluation (ACE) over time

    baseline, immediate follow-up, and at a 6 month follow-up

Other Outcomes (10)

  • Mean Change on Everyday Cognition Scale (ECog)

    baseline, immediate follow-up, and at a 6 month follow-up

  • Mean Change on Pittsburgh Sleep Quality Index (sleep)

    baseline, immediate follow-up, and at a 6 month follow-up

  • Mean Change on Framingham Cardiovascular Risk Score

    baseline, immediate follow-up, and at a 6 month follow-up

  • +7 more other outcomes

Study Arms (5)

MediTrain 30m/day for 6wks

EXPERIMENTAL

Participants will engage with a digital meditation app for the time listed above.

Device: MediTrain

MediTrain 15m/day for 6wks

EXPERIMENTAL

Participants will engage with a digital meditation app for the time listed above.

Device: MediTrain

MediTrain 30m/day for 3wks

EXPERIMENTAL

Participants will engage with a digital meditation app for the time listed above.

Device: MediTrain

MediTrain 15m/day for 3wks

EXPERIMENTAL

Participants will engage with a digital meditation app for the time listed above.

Device: MediTrain

Active Control Group

ACTIVE COMPARATOR

An active control application will be used for this arm. The total training experience here will be for 6 weeks (5 days/week), with each training session lasting \~30 minutes (not including self-paced breaks). Here an app that is matched in terms of expectancy of benefits compared to our training groups will be determined by questioning 100 naïve individuals to predict their expected improvement on each cognitive domain across a multitude of possible applications.

Device: Worder

Interventions

MediTrainDEVICE

MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.

MediTrain 15m/day for 3wksMediTrain 15m/day for 6wksMediTrain 30m/day for 3wksMediTrain 30m/day for 6wks
WorderDEVICE

Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.

Active Control Group

Eligibility Criteria

Age60 Years - 99 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • + years old (adult)
  • English language fluency
  • owning a smartphone or tablet

You may not qualify if:

  • Under 60 years old (minor)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California San Francisco

San Francisco, California, 94158, United States

RECRUITING

MeSH Terms

Conditions

Cognitive DysfunctionDementiaBehavior

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Adam Gazzaley, MD/PhD

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR
  • David Ziegler, PhD

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR

Central Study Contacts

David Ziegler, PhD

CONTACT

Monique de Villa, MS, MPH

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
double blind
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 23, 2024

First Posted

May 3, 2024

Study Start

April 1, 2024

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

June 1, 2029

Last Updated

February 24, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations